News Related to Relatlimab

Related coverage linked through entity extraction aliases.

Early ctDNA Changes Predict Survival in Advanced Melanoma Treated With Immunotherapy

Mar 13, 2026

Decreases in circulating tumor DNA within 3-4 weeks of immune checkpoint inhibitor therapy were strongly associated with higher response rates and longer survival in patients with unresectable stage III/IV melanoma, according to a multi-institutional retrospective analysis.

Biomarkers and T Cell Traits Emerge as Key Predictors of Cancer Immunotherapy Response

Feb 17, 2026

New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.